Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 366

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 366
---
 December 2014 until admission of the Company’s ordinary shares to trading on AIM was cancelled 26 April 2023.

In addition, since 4
December 2015 the Company has American Depository Receipts (‘ADRs’) registered with the US Securities and Exchange Commission
(‘SEC’) and is listed on the NASDAQ Capital Market.

On 27 March 2023 the
company changed its name to Biodexa Pharmaceuticals PLC from Midatech Pharma Plc.

The financial statements
were approved and authorised for issue by the Board of Directors on 18 April 2024.

Basis of preparation

The Group was formed
on 31 October 2014 when the Company entered into an agreement to acquire the entire share capital of Biodexa Limited and its wholly owned
subsidiaries through the issue equivalent of shares in the Company which took place on 13 November 2014.

These financial statements
have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards
Board (IASB).

The principal accounting
policies adopted in the preparation of the financial statements are set out below. The policies have been consistently applied to all
the periods presented.

The consolidated financial
statements have been prepared on a historical cost basis, except for the following item (refer to individual accounting policies for details):

- Certain financial
instruments – fair value through profit or loss.

Adoption of new
and revised standards

New standards, interpretations and amendments effective from 1 January 2023

The Group reviewed the
new standards, interpretations and amendments effective from 1 January 2023 and deemed none were applicable to the annual financial statements
for the year ended 31 December 2023.

New standards, interpretations and amendments not yet effective

There are a number of standards, amendments to standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the group has decided not to adopt early.

The Group reviewed the new standards, interpretations and amendments effective from 1 January 2024 and 1 January 2025 and deemed none have a material impact on the group.

| F-31 |

| 1 | Accounting policies (continued) |

Basis for consolidation

The Group financial statements consolidate those of the parent company and all of its subsidiaries. The parent controls a subsidiary if it has power over the investee to significantly direct the activities, exposure, or rights to variable returns from its involvement with the investee, and the ability to